Taysha Gene Therapies price target raised to $6 from $5 at Citizens JMP

Citizens JMP raised the firm’s price target on Taysha Gene Therapies (TSHA) to $6 from $5 and keeps an Outperform rating on the shares. Taysha Gene Therapies reported positive clinical data from Part A of the REVEAL adult/ adolescent and pediatric cohorts evaluating TSHA-102 in females with Rett syndrome at the low dose and at the high dose and also announced written alignment with the FDA on the design of the pivotal study which will initiate in 3Q25, the analyst tells investors in a research note. Citizens views the data around the objectivity of the endpoint as a positive, along with the alignment with the FDA.